I am a Postdoctoral researcher in the IMED Biotech unit at AstraZeneca Gothenburg. I am part of the Discovery Sciences team, which develops new scientific methods for drug discovery. Discovery Sciences at AstraZeneca uses advanced screening methods of compounds to contribute to the early discovery of potential new drugs, and supports other teams with delivering reagents, assays and disease models to discover new targets and medicines.

 

I completed my academic studies at the University of Helsinki, where I received my Ph.D. from the School of Pharmacy in 2017. As part of my education, I also spent one year as visiting researcher at the University of Gothenburg.

 


The field of extracellular vesicles grows rapidly, and represents a new era in diagnosis and treatment of diseases. The knowledge gained from our daily work is also of great importance to our general research on personalized medicine, which will give future patients new opportunities to fight their diseases.

Elisa Lázaro Ibáñez Postdoctoral Researcher - IMED Biotech Unit, AstraZeneca Gothenburg

During my academic career, I investigated the emerging field of extracellular vesicles, including so-called `Exosomes´. Extracellular vesicles are nature’s small transport vesicles that interact with many different cell types in the body mediating physiological and pathological functions. I researched the potential use of extracellular vesicles for the diagnosis and treatment of cancer. I discovered, among other things, how vesicles act as reservoirs for biomarkers, which can aid early diagnosis of cancer and help to identify which patients respond best to certain treatments. In 2017, my work was awarded the `Most Outstanding Doctoral Thesis´ in Pharmaceutical Sciences in Finland.

I started at AstraZeneca as Postdoctoral Researcher in March 2017. Today, I work primarily with developing techniques for loading extracellular vesicles with therapeutic molecules and targeting them to disease tissues.

 


I am particularly interested in exploring the possibilities of using extracellular vesicles as biomarkers and in the delivery of therapeutics for future treatments. The use of extracellular vesicles can lead to faster, improved and more individualized diagnoses and treatments tailored to specific needs of patients.

Elisa Lázaro Ibáñez Postdoctoral Researcher - IMED Biotech Unit, AstraZeneca Gothenburg